An 80-mg dose of atorvastatin administered 12 hours before angioplasty, followed by a 40-mg dose administered 2 hours before the procedure significantly reduces the risk of major cardiovascular events during the month after the intervention, according to the results of The Atorvastatin for Reduction of Myocardial Damage during Angioplasty-Acute Coronary Syndromes (ARMYDA-ACS) trial.
An 80-mg dose of atorvastatin administered 12 hours before angioplasty, followed by a 40-mg dose administered 2 hours before the procedure significantly reduces the risk of major cardiovascular events during the month after the intervention, according to Germano Di Sciascio, MD, professor and chairman of cardiology and director of cardiovascular sciences, Campus Bio-Medico University of Rome, Italy.
"Lipid-independent pleiotropic actions of atorvastatin may explain such rapid effects," Dr Di Sciascio said. Anti-inflammatory, antithrombotic, or vascular effects that improve outcomes may be responsible for the rapid effect of atorvastatin in this setting, he added.
The primary end point was occurrence of death, MI, or need for revascularization at 30 days after angioplasty.
Seventeen percent of placebo recipients versus 5% of atorvastatin-treated patients met the primary end point. After multivariate adjustment, this difference amounted to an 88% reduction (P=.004) in major cardiovascular events with atorvastatin pretreatment. "This was mostly driven by a 70% reduction in peri-procedural MI in the atorvastatin group," Dr Di Sciascio said.
The markers of cardiac injury, troponin-I and creatine kinase-MB, were significantly lower in the atorvastatin group compared with placebo when measured 30 days after intervention.
Patients on current statin therapy were excluded from the study; so it is unclear whether patients on chronic statin treatment would have a clinical benefit similar to the one observed with acute administration, Dr Di Sciascio said.
The results of the ARMYDA-ACS trial have since been published in the Journal of the American College of Cardiology (2007;49:1272–1278).
AstraZeneca, Daiichi Sankyo Submit New BLA for Datopotamab in Lung Cancer
November 12th 2024After feedback from the FDA, the companies have voluntarily withdrawn the previous biologics licensing application for datopotamab deruxtecan for patients with advanced or metastatic nonsquamous non-small cell lung cancer.
Read More
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
Skyrizi Overtakes Humira in U.S. Sales Numbers
November 8th 2024For the first time, Skyrizi has replaced Humira as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.
Read More